Recent study on dietary modifications and supplement use for endometriosis pain aimed to investigate the effectiveness of ...

Organon said on Wednesday it will the stop development of an experimental treatment it acquired through its purchase of Forendo Pharma, after the drug failed to reduce pelvic pain in women with ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health. New drugs for obesity ...

Gentle yoga for endometriosis and pelvic pain 💛 A 20-minute practice to soothe tension, promote relaxation, and support your body with care.#EndometriosisYoga #PelvicPainRelief #GentleYoga #YogaForWo ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Pain reduction: A study found that 63% of people with endometriosis experienced an improvement in pain after six sessions of pelvic floor therapy. Improved sexual function: By addressing muscle ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in ...

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Physicians are urged to consider childhood trauma when women present with pelvic pain or dysmenorrhea as early hardships may ...

A recent study finds that a low FODMAP diet significantly reduces gastrointestinal symptoms in women with endometriosis, ...